Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.

Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Mar 2003Cited by 163 (Europe PMC)

PMID12619939DOI10.1359/jbmr.2003.18.3.539PepBankPUB-12619939

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, total radial bone mineral density did not differ among teriparatide and placebo groups.
In plain wordsIn women with osteoporosis, total radial bone density was similar across teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal bone mineral density
Study
n = 101
Comparator
Placebo and other teriparatide dose
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in total bone mineral density, cortical thickness, cortical bone mineral density, or cortical bone mineral content among groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993913
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, radial cortical thickness did not differ among teriparatide and placebo groups.
In plain wordsIn women with osteoporosis, cortical thickness at the radius was similar across teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical thickness
Study
n = 101
Comparator
Placebo and other teriparatide dose
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in total bone mineral density, cortical thickness, cortical bone mineral density, or cortical bone mineral content among groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993914
03HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, radial cortical bone mineral density did not differ among teriparatide and placebo groups.
In plain wordsIn women with osteoporosis, cortical bone density at the radius was similar across teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical bone mineral density
Study
n = 101
Comparator
Placebo and other teriparatide dose
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in total bone mineral density, cortical thickness, cortical bone mineral density, or cortical bone mineral content among groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993915
04HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, radial cortical bone mineral content did not differ among teriparatide and placebo groups.
In plain wordsIn women with osteoporosis, cortical bone mineral content at the radius was similar across teriparatide and placebo groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical bone mineral content
Study
n = 101
Comparator
Placebo and other teriparatide dose
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
There were no differences in total bone mineral density, cortical thickness, cortical bone mineral density, or cortical bone mineral content among groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993916
05HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, lower-dose teriparatide increased distal radial total bone mineral content versus placebo.
In plain wordsIn women with osteoporosis, lower-dose teriparatide increased total bone mineral content at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal bone mineral content, lower dose
Study
n = 73
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Total bone mineral content, total and cortical bone areas, periosteal circumference, and polar cross-sectional moment of inertia were also significantly higher in the patients treated with teriparatide 20 microg compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993908
06HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, lower-dose teriparatide increased distal radial total bone area versus placebo.
In plain wordsIn women with osteoporosis, lower-dose teriparatide increased total bone area at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal bone area, lower dose
Study
n = 73
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Total bone mineral content, total and cortical bone areas, periosteal circumference, and polar cross-sectional moment of inertia were also significantly higher in the patients treated with teriparatide 20 microg compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993909
07HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, lower-dose teriparatide increased distal radial cortical bone area versus placebo.
In plain wordsIn women with osteoporosis, lower-dose teriparatide increased cortical bone area at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone area, lower dose
Study
n = 73
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Total bone mineral content, total and cortical bone areas, periosteal circumference, and polar cross-sectional moment of inertia were also significantly higher in the patients treated with teriparatide 20 microg compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993910
08HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, lower-dose teriparatide increased distal radial periosteal circumference versus placebo.
In plain wordsIn women with osteoporosis, lower-dose teriparatide increased outer bone circumference at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal circumference, lower dose
Study
n = 73
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Total bone mineral content, total and cortical bone areas, periosteal circumference, and polar cross-sectional moment of inertia were also significantly higher in the patients treated with teriparatide 20 microg compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993911
09HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, lower-dose teriparatide increased the distal radial polar cross-sectional moment of inertia versus placebo.
In plain wordsIn women with osteoporosis, lower-dose teriparatide increased a polar measure of bone geometry compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePolar cross-sectional moment of inertia, lower dose
Study
n = 73
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Total bone mineral content, total and cortical bone areas, periosteal circumference, and polar cross-sectional moment of inertia were also significantly higher in the patients treated with teriparatide 20 microg compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993912
10HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased distal radial total bone mineral content versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased total bone mineral content at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal bone mineral content, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993901
11HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased distal radial total bone area versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased total bone area at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal bone area, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993902
12HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased distal radial cortical bone area versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased cortical bone area at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone area, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993903
13HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased distal radial periosteal circumference versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased outer bone circumference at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePeriosteal circumference, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993904
14HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased distal radial endocortical circumference versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased inner cortical circumference at the radius compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical circumference, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993905
15HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased the distal radial axial cross-sectional moment of inertia versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased an axial measure of bone geometry compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseAxial cross-sectional moment of inertia, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993906
16HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, higher-dose teriparatide increased the distal radial polar cross-sectional moment of inertia versus placebo.
In plain wordsIn women with osteoporosis, higher-dose teriparatide increased a polar measure of bone geometry compared with placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreasePolar cross-sectional moment of inertia, higher dose
Study
n = 63
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 18 monthsAs given in this study (human).
Source sentences
Summary
Compared with placebo, patients treated with teriparatide 40 microg had significantly higher total bone mineral content, total and cortical bone areas, periosteal and endocortical circumferences, and axial and polar cross-sectional moments of inertia.
2 context sentences(design, population, supporting numbers)
Summary · context
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo…
Summary · context
We obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Report a problemFND-1261993907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.